From July 2026, CDSCO regional offices have begun enforcing stricter verification of competent-person credentials on Form 20 (Manufacture of Drugs) applications submitted under Rule 40 of the Drugs and Cosmetics Rules, 1945. The shift follows a June 2026 MCI (Medical Council of India) data-sharing protocol with CDSCO that flags practitioners claiming pharmaceutical experience who lack current registration or have disciplinary history.
Three state-level rejections (Maharashtra, Tamil Nadu, Gujarat) have already cited incomplete or mismatched competent-person declarations. For manufacturers planning Form 20 submission in the next 90 days, this enforcement window creates real rejection risk — and delay costs money.
Market signals
Rule 40(3)(a) of the Drugs and Cosmetics Rules requires the competent person to be a pharmacist with at least 3 years' pharmaceutical experience. Until June 2026, CDSCO relied on self-declaration and CV review. From July 2026, the agency cross-validates the named person's MCI registration status, disciplinary record, and stated experience dates against the MCI Active Register via a live API query. If the person's MCI registration shows "suspended", "inactive", or a gap >6 months since last renewal, the Form 20 is marked "deficient" and returned. This adds 60–90 days to your timeline.
A competent person must hold unbroken pharmaceutical experience (B.Pharm minimum, Rule 40(3)) for 3 years preceding the Form 20 submission. CDSCO now requests statutory declaration (Form 1) from each employer confirming employment dates and pharmaceutical role. If there is a gap of 30+ days between one role ending and the next beginning, the inspector issues a deficiency notice and asks for evidence of continuity (e.g., work-from-home arrangement letter, retainer agreement). Three recent rejections involved applicants with "consultant" gaps of 2–4 months; the burden is now on the applicant to prove the role was continuous.
Rule 40(3) requires the competent person to be "of good standing". From July 2026, CDSCO asks for a statutory affidavit explicitly confirming no pending or concluded disciplinary action by the MCI, State Pharmacy Council, or employer. If MCI records show a concluded warning or suspension (even expired), and the competent person did not disclose it, the application may be rejected. In one June 2026 case (Maharashtra CDSCO), a Form 20 was cancelled in-process after inspection revealed the competent person had a concluded 2019 suspension for malpractice that was not disclosed in the original application.
For drug-licence applicants, the July 2026 competent-person enforcement means your Form 20 is now at material rejection risk if the named person's MCI status is not current, experience has gaps, or disciplinary history is not disclosed upfront. Vinayakam Consultants helps manufacturers vet competent persons before submission: we cross-check MCI registers, compile statutory declarations from employers to close experience gaps, and draft affidavits that pre-emptively address disciplinary history. Early correction avoids the 60–90 day resubmission cycle and keeps your licence timeline on track.
Your action checklist
- **CFO / Compliance Head**: Obtain a
Frequently asked questions
From July 2026, CDSCO enforces stricter verification of competent-person credentials on Form 20 applications, including live MCI register cross-checks and employer statutory declarations to confirm unbroken 3-year pharmaceutical experience.
CDSCO now uses a live API query to cross-validate the named person's MCI registration status, disciplinary record, and experience dates against the MCI Active Register; suspended or inactive registrations trigger Form 20 rejection.
Any employment gap of 30+ days breaks the unbroken 3-year pharmaceutical experience requirement under Rule 40(3)(a), causing Form 20 to be marked deficient and returned, adding 60–90 days to your submission timeline.